Results 161 to 170 of about 70,554 (222)

Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors. [PDF]

Cancer Res Commun
Kanemura H, Takehara T, Maenishi O, Tomida S, Iwawaki N, Kunimasa K, Nakayama T, Watanabe S, Suzuki S, Sakai K, Azuma K, Kudo K, Nishio K, Nakagawa K, Hayashi H, Teramura T, Yonesaka K.   +16 more
europepmc   +1 more source

Analysis of the efficacy of camrelizumab/cetuximab neoadjuvant therapy in patients with loco-regionally advanced laryngeal and hypopharyngeal cancer and the prognostic value of NLR/SII. [PDF]

World J Surg Oncol
Cai N, Wei H, Chen Y, Wang J, Li P, Hao C.   +5 more
europepmc   +1 more source

Epidermal growth factor receptor-targeted near-infrared probe cetuximab-IRDye800CW enables stable and tumor-specific fluorescence imaging in colorectal cancer models. [PDF]

J Biomed Opt
Huang Y, Zhang X, Jiang Y, Wang D.
europepmc   +1 more source

Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. [PDF]

Clin Cancer Res
Chaudhary R, Moorhead G, Park R, Li J, Schell MJ, Song X, Tan A, Slebos RJC, Biernacki MI, Freeman SS, Thatikonda S, Meshkovska Y, Hernandez-Prera J, Kirtane K, Guevara-Patino JA, Amelio AL, Rocco JW, Danysh BP, Bonomi M, Saba NF, Haradhvala NJ, Getz G, Chung CH.   +22 more
europepmc   +1 more source

Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib. [PDF]

J Clin Med
Kawczak P, Bączek T.
europepmc   +1 more source

Cost-effectiveness of first-line encorafenib plus cetuximab with mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer. [PDF]

iScience
Shu Y, Shi F, Xiong J, Zheng J, Ding Y, Zhang W, Xu P, Zhang Q.   +7 more
europepmc   +1 more source

State of the Art of Systemic Therapy in HPV-Positive Oropharyngeal Squamous Cell Carcinoma: A Scoping Review. [PDF]

Diseases
Petrelli F, Ghilardi M, De Stefani A, Nardone M, Capriotti V.   +4 more
europepmc   +1 more source

Simulation-based assessment of a Bayesian M-spline survival model with flexible baseline hazard and time-dependent effects. [PDF]

BMC Med Res Methodol
Timmins IR, Torabi F, Jackson CH, Lambert PC, Sweeting MJ.   +4 more
europepmc   +1 more source

circ-EGFR is a predictor of response to Cetuximab and a potential target in colorectal cancer. [PDF]

EMBO Mol Med
Sui S, Li Y, Maurel J, Goel A.
europepmc   +1 more source

Correction: Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. [PDF]

Mol Cancer
Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL.   +9 more
europepmc   +1 more source